S
Sylvie van der Werf
Researcher at Pasteur Institute
Publications - 235
Citations - 17249
Sylvie van der Werf is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Influenza A virus & Virus. The author has an hindex of 48, co-authored 235 publications receiving 14083 citations. Previous affiliations of Sylvie van der Werf include Centre national de la recherche scientifique & World Health Organization.
Papers
More filters
Journal ArticleDOI
Standardization and validation of assays determining cellular immune responses against influenza.
Karlijn Gijzen,Wai Ming Liu,Ildiko Visontai,Fredrik Oftung,Sylvie van der Werf,Gro Ellen Korsvold,Inge Pronk,Ingeborg S. Aaberge,Anna Tütto,Istvan Jankovics,Mate Jankovics,Beth Gentleman,Janet E. McElhaney,Ernst C. Soethout +13 more
TL;DR: The precision and robustness of these cellular assays allow the reliable detection of cellular responses even in small study populations, and can now be used for determining cell-mediated immunity and explored as correlates of protection.
Journal ArticleDOI
The transcription/replication activity of the polymerase of influenza A viruses is not correlated with the level of proteolysis induced by the PA subunit.
TL;DR: It is observed that the ability of PR8-PA to induce proteolysis was severely impaired at 33 degrees C as compared to 37 degrees C, while the efficiency with which thePR8-derived polymerase complex ensured transcription/replication of the viral-like RNA was similar at both temperatures.
Journal ArticleDOI
Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Vanessa Escuret,Catherine Cornu,Catherine Cornu,Florent Boutitie,Vincent Enouf,Anne Mosnier,M. Bouscambert-Duchamp,Ségolène Gaillard,Ségolène Gaillard,Xavier Duval,Xavier Duval,Thierry Blanchon,Catherine Leport,François Gueyffier,François Gueyffier,Sylvie van der Werf,Bruno Lina +16 more
TL;DR: The sample size of this study is too limited to be fully informative and it could not detect whether combination therapy (O+Z) improves or reduces the effectiveness of oseltamivir in the treatment of influenza A(H1N1)pdm09 virus infection in community patients.
Journal ArticleDOI
2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.
Esther Kissling,Marta Valenciano,Francisco Pozo,Ana-Maria Vilcu,Annicka Reuss,Caterina Rizzo,Amparo Larrauri,Judit Krisztina Horváth,Mia Brytting,Lisa Domegan,Monika Roberta Korczyńska,Adam Meijer,Ausenda Machado,Alina Elena Ivanciuc,Vesna Višekruna Vučina,Sylvie van der Werf,Brunhilde Schweiger,Antonino Bella,Alin Gherasim,Annamária Ferenczi,Katherina Zakikhany,Joan O Donnell,Iwona Paradowska-Stankiewicz,Frederika Dijkstra,Raquel Guiomar,Mihaela Lazar,Sanja Kurečić Filipović,Kari Johansen,Alain Moren +28 more
TL;DR: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.
Journal ArticleDOI
Neuraminidase of 2007–2008 Influenza A(H1N1) Viruses Shows Increased Affinity for Sialic Acids Due to the D344N Substitution:
Marie-Anne Rameix-Welti,Sandie Munier,Sebastien Le Gal,Frédérique Cuvelier,Fabrice Agou,Vincent Enouf,Nadia Naffakh,Sylvie van der Werf +7 more
TL;DR: The D344N substitution characteristic of the N1 of 2007-2008 A(H1N1) viruses was identified as a major determinant of its increased affinity for sialic acids.